New Key Statistics Module, Z-Score and F-Score
NAS:NTLA Key Ratios
| Market Cap $ M | 1,038.86 |
| Enterprise Value $ M | 482.36 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 1.08 |
| Price/Sales | 22.97 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 43.00 |
| EPS (TTM) $ | -5.44 |
| Beneish M-Score | -2.34 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -28.30 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.90 |
| EV-to-EBITDA | -0.91 |
| PEG | -- |
| Shares Outstanding M | 101.85 |
| Net Margin (%) | -1,212.19 |
| Operating Margin % | -1,247.99 |
| Pre-tax Margin (%) | -1,212.19 |
| Quick Ratio | 6.73 |
| Current Ratio | 6.73 |
| ROA % (ttm) | -42.33 |
| ROE % (ttm) | -51.64 |
| ROIC % (ttm) | -121.50 |
| Dividend Yield % | -- |
| Altman Z-Score | -0.30 |
NTLA Number of Guru Trades
NTLA Volume of Guru Trades
Gurus Latest Trades with NAS:NTLA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:NTLA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Intellia Therapeutics Inc Insider Transactions
No Available Data
News about NAS:NTLA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers